L’arrivée des bithérapies dans le traitement du virus de l’immunodéficience humaine : la fin d’un dogme?

Current guidelines increasingly consider some dual antiretroviral therapies as bona fide alternatives to triple therapy as these regimens are proven to be safe and efficacious. These drug sparing regimens have many advantages such as a reduction of drug burden and subsequent toxicity, preservation of future treatment options, cost reduction and avoidance of drug-drug interactions. In the past, some dual therapies were associated with a higher risk of selecting resistance mutations. Nevertheless, current and future dual regimens based on powerful drugs with a high genetic barrier are non-inferior to triple therapies and could become the future gold standard for HIV treatment.